Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(02): 169-174
DOI: 10.1055/s-0041-1735583
Original Article

A Microbiological Study of Acinetobacter calcoaceticus baumannii with Special Reference to Multidrug Resistance

Langamba Angom Longjam 
1   Department of Microbiology, Sikkim Manipal Institute of Medical Sciences, Gangtok, Sikkim, India
,
Dechen Chomu Tsering
1   Department of Microbiology, Sikkim Manipal Institute of Medical Sciences, Gangtok, Sikkim, India
,
Dipmala Das
2   Department of Microbiology, IQ City Medical College and Hospital, Durgapur, West Bengal, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction The outbreak of Acinetobacter calcoaceticus baumannii (ACB) is mainly reported to be a notorious pathogens at health-care settings. It is the major problem on the health-care system with high morbidity and mortality rates because of the broad range of antibiotic resistance and lack of understanding the mechanism of developing new antibiotic resistance rapidly. It emphasizes the importance of local surveillance in describing or understanding and predicting microbial resistance patterns so that there will be limited use of antibiotics by developing strategies to control the extensive use of antimicrobial chemotherapy in clinical environment, which is still considered as one of the factors in the emergence of multidrug resistance microorganisms.

Objectives The study aims to detect the occurrence rate of ACB infections from various clinical samples, identify the resistance levels to different groups of antimicrobial agents, and the occurrence rate of multidrug resistant (MDR) ACB clinical isolates from a tertiary hospital in Durgapur, West Bengal, India.

Material and Methods The study was performed in the Department of Microbiology of the IQ City Medical College and Hospital, Durgapur, West Bengal, India, for the 24 months duration, that is, from January 1, 2018 to December 31, 2019. Altogether 15,800 clinical samples consisting of endotracheal tube aspirates, sputum, pus, blood, catheter tips, urine, tissue, and other body fluids were studied. ACB from clinical samples were identified by its characteristic colonies (nonlactose fermenting, glistening, small mucoid colonies), Gram-staining pattern (Gram-negative coccobacillus), and standard biochemical reactions. It was further confirmed in the Department of Microbiology of the Healthworld Hospital, Durgapur, West Bengal, India, by Vitek2 compact system (bioMerieux, Inc., Durham, North Carolina, United States). Antibiotic susceptibility testing was performed using automated broth microdilutions by Vitek2 compact system (bioMerieux, Inc.) and Kirby-Bauer disk diffusion test on Mueller-Hinton Agar (HiMedia).

Results Nonrepetitive 289 ACB were isolated from various clinical samples. A total of 277 (96%) isolates of ACB were MDR strains.

Conclusion ACB was mostly isolated from the intensive care unit department and was found to be the most MDR type in the tertiary care hospital by this study.

Keywords

Acinetobacter calcoaceticus baumannii - antibiotic susceptibility testing - MDR strains - Vitek2 compact system

Source(s) of Support

None.


Authors' Contributions

L.L.A.: Literature search, review of literature, manuscript preparation, concept and design of the study, data collection, statistically analyzed and interpreted, prepared first draft of manuscript, and critical review of study proposal.


D.C.T.: Scientific advisor, critical review of study proposal, and helped in preparing first draft of manuscript.


D.D.: Scientific advisor, critical review of study proposal, and data collection.




Publication History

Article published online:
22 September 2021

© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Centers for Disease Control. Overview of Drug-resistant Acinetobacter infections in healthcare settings. Centers for Disease Control and Prevention. Accessed February 18, 2017 at: www.cdc.gov/ncidod/dhqp/ar_acinetobacter.html
    Google Scholar
  • 2 Manchanda V, Sanchaita S, Singh N. Multidrug resistant acinetobacter. J Glob Infect Dis 2010; 2 (03) 291-304
    CrossrefPubMedGoogle Scholar
  • 3 Corbella X, Pujol M, Ayats J. et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis 1996; 23 (02) 329-334
    CrossrefPubMedGoogle Scholar
  • 4 Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11 (01) 22-29
    CrossrefPubMedGoogle Scholar
  • 5 Hsueh P-R, Teng L-J, Chen C-Y. et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002; 8 (08) 827-832
    CrossrefPubMedGoogle Scholar
  • 6 Fernández-Cuenca F, Martínez-Martínez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003; 51 (03) 565-574
    CrossrefPubMedGoogle Scholar
  • 7 Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 (Suppl. 02) S100-S105
    CrossrefPubMedGoogle Scholar
  • 8 Bergogne-Bérézin E. The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J Hosp Infect 1995; 30 (Suppl): 441-452
    CrossrefPubMedGoogle Scholar
  • 9 Go ES, Urban C, Burns J. et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994; 344 (8933): 1329-1332
    CrossrefPubMedGoogle Scholar
  • 10 Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5 (12) 939-951
    CrossrefPubMedGoogle Scholar
  • 11 Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21 (03) 538-582
    CrossrefPubMedGoogle Scholar
  • 12 Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12 (09) 826-836
    CrossrefPubMedGoogle Scholar
  • 13 Wareham DW, Bean DC, Khanna P. et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008; 27 (07) 607-612
    CrossrefPubMedGoogle Scholar
  • 14 Souli M, Kontopidou FV, Koratzanis E. et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006; 50 (09) 3166-3169
    CrossrefPubMedGoogle Scholar
  • 15 Clinical and Laboratory Standards Institute (CLSI).. Performance Standards for Antimicrobial Susceptibility Testing (M100S). 28th ed.. Wayne, PA: CLSI; 2018
    Google Scholar
  • 16 Talukdar A, Hodiwala AB, Sharma R. Amicrobiological study of Acinetobacter baumannii with special reference to multi-drug resistance. Int J Curr Microbiol Appl Sci 2018; 7 (02) 2319-7706
    Google Scholar
  • 17 Khan ID, Basu A, Kiran S, Trivedi S, Pandit P, Chattoraj A. Device-Associated Healthcare-Associated Infections (DA-HAI) and the caveat of multiresistance in a multidisciplinary intensive care unit. Med J Armed Forces India 2017; 73 (03) 222-231
    CrossrefPubMedGoogle Scholar
  • 18 Banerjee T, Mishra A, Das A, Sharma S, Barman H, Yadav G. High prevalence and endemicity of multidrug resistant Acinetobacter spp. in intensive care unit of a tertiary care hospital, Varanasi, India. J Pathogens 2018; 2018: 9129083
    CrossrefPubMedGoogle Scholar
  • 19 Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58 (05) 1099-1100
    CrossrefPubMedGoogle Scholar
  • 20 Mehrad B, Clark NM, Zhanel GG, Lynch III JP. Antimicrobial resistance in hospital-acquired Gram-negative bacterial infections. Chest 2015; 147 (05) 1413-1421
    CrossrefPubMedGoogle Scholar